After yesterday's 9 percent beating, the Thousand Oaks-based drug firm is down nearly 3 percent, to $55.64. Never mind that it's now hovering at its 52-week low - what investors should really worry about is that Wall Street wants out. At least five different research groups, including Citigroup and Morgan Stanley, lowered their ratings this morning after an FDA advisory panel said that the company's anti-anemia drugs should have additional restrictions on product labels.
More by Mark Lacter:
Barry Diller's many paychecksSay hello to the marijuana vending machine - and it's made in California
Good tip for job candidates: Always ask questions
Former Calpers CEO charged with fraud*
The Walmart story that everyone is talking about
Recent stories on LA Observed:
Barry Diller's many paychecksSay hello to the marijuana vending machine - and it's made in California
Good tip for job candidates: Always ask questions
Former Calpers CEO charged with fraud*
The Walmart story that everyone is talking about
New at LA Observed
Follow us on Twitter
On the Media Page
Go to Media
LA Biz Observed
Go to LA Biz Observed
Sign up for daily email from LA Observed
Annual issue is out this week